Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
← catalyst calendarNCT07711002 · readout in 1,763 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
1,330estimated
Sites
2
Country
Canada
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-10-01 | estimated | When the study began enrolling |
| Primary completion | 2031-06-17 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2033-06-14 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions
- Drug: Saruparib
- Other: Placebo
- Drug: Enzalutamide
- Drug: Darolutamide
- Drug: Abiraterone
Primary outcome
what the primary-completion date above is the date OFRadiographic progression-free survival (rPFS)
measured Up to approximately 56 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed